Daxor Corporation Announces LA County USC Hospital To Obtain the BVA-100 Blood Volume Analyzer for Critical Care Unit.

NEW YORK -- Daxor Corporation, (AMEX:DXR), a medical instrumentation and biotechnology company, today announced the receipt of an agreement from the LA County USC Hospital in Los Angeles, California to acquire a BVA-100 Blood Volume Analyzer. The equipment will be placed in the Critical Care Unit.

Los Angeles County + University of Southern California Medical Center (LAC + USC) is one of the largest acute care hospitals in the United States and the largest single provider of healthcare in the County. The General Hospital provides a full spectrum of emergency, inpatient and outpatient services which include medical, surgical and emergency/trauma services. LAC+USC also provides the community with more than 28% of its trauma care and operates one of three burn centers in the County. LAC+USC is also the nation's largest academic institution. It has served as the primary facility of the University of Southern California School of Medicine since 1885.

Dr. William Shoemaker, Professor of Surgery and Anesthesiology at LAC+USC Hospital said "We are delighted with the opportunity to use the new blood volume instrument in our Trauma/Critical Care Unit. We have extensively used an older, now obsolete blood volume measurement system. We had found that blood volume measurements were crucial in the management of acute critical illnesses associated with shock from trauma, high-risk surgery, sepsis, and burns. We had found that most circulatory disorders have blood volume alterations as the underlying basis of their blood pressure, heart rate and blood flow abnormalities. Blood volume alterations are commonly seen as the basis of shock and hemodynamic alterations after trauma and high-risk surgery. It is important to treat the specific underlying circulatory condition, such as hypovolemia, rather than to correct secondary manifestations of circulatory failure, which is like treating the symptoms rather than the primary problem. Early correction of blood volume abnormalities may be useful in preventing circulatory failure and its complications, including organ failure, and in some cases death."

Daxor Corporation manufactures and markets the BVA-100, a semi-automated Blood Volume Analyzer. The BVA-100 is used in conjunction with a single use diagnostic kit. The BVA-100 measures blood volume to within a 98% accuracy. More information about the BVA-100 and other Daxor products and services can be found at www.daxor.com.